Cannabist Co Holdings Inc.
Cannabist Co Holdings Inc., formerly Columbia Care, is a U.S. cannabis operator that cultivates, manufactures, and sells cannabis products through a multi-state network of dispensaries and production facilities. The company operates in 12 U.S. jurisdictions and runs 71 facilities, including 53 dispensaries and 18 cultivation/manufacturing sites under development or in operation. Its business spans both medical and adult-use cannabis, with retail sold under the Cannabist brand and products distributed through its own stores and branded product lines. The company’s portfolio includes flower, edibles, oils, and tablets, along with a set of house brands such as dreamt, Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, and Amber.
Fiscal year 2024 · change from previous year
Development 2020–2024
Business
Share of revenueCannabist-branded stores that sell cannabis products directly to medical patients and adult-use consumers.
Growing, processing, and manufacturing operations that supply the company’s own retail network and wholesale channels.
Packaged flower, edibles, oils, tablets, and other products sold under proprietary brands.
Product sales and related support services to third-party dispensaries and market participants where permitted.
Products
Reported · share of revenue- Dispensary84.9 %
- Cultivation and Wholesale15.1 %
Source: 10-K FY2024, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
The company serves two core end markets: medical cannabis patients and adult-use consumers. Medical customers buy cannabis products for therapeutic use in states where the company holds licenses, while adult-use customers purchase for recreational consumption in legalized markets. A meaningful part of the business also depends on wholesale and supply relationships with other licensed cannabis operators and dispensaries. Because cannabis remains regulated at the state level, customer access and product mix vary by jurisdiction and by the maturity of each local market.
Patients in licensed jurisdictions who buy cannabis products for symptom relief and ongoing treatment needs.
Recreational customers purchasing through the Cannabist retail network in legalized markets.
Other licensed operators and dispensaries that buy product supply where the company can sell outside its own stores.
Customers who seek specific product lines such as dreamt, Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, and Amber.
Strategy
The company’s near-term focus is on preserving liquidity, controlling operating expenses, and improving operating performance in a difficult capital environment. Management states that future results will depend on sales growth in existing and new markets, as well as the ability to manage costs and adapt to changing local, state, and federal regulation. The company also remains open to expansion or acquisition opportunities, but those plans are constrained by financing availability and the need to support ongoing operations. In practice, the strategy is centered on stabilizing the balance sheet while keeping the retail and cultivation platform positioned for selective growth.
The company has sustained losses and needs capital to fund operations, debt obligations, and capital expenditures.
Margins and cash flow are pressured by inflation, regulatory complexity, and a challenging cannabis market.
Growth depends on adding sales volume in new and existing jurisdictions without overextending the balance sheet.
Geography
Cannabist operates in 12 U.S. jurisdictions, making its business highly dependent on state-by-state cannabis regulation and licensing. Its 71 facilities are spread across retail and production sites, with 53 dispensaries and 18 cultivation/manufacturing facilities, including some under development. The company’s revenue and operating footprint are concentrated in the United States, and it does not disclose a country-level revenue split in the provided excerpts. Geographic expansion is strategic because each new jurisdiction can add retail access, cultivation capacity, and branded product distribution, but it also increases regulatory, compliance, and execution complexity.
Risks
The most material company-specific risk is liquidity and going-concern pressure, as management discloses substantial doubt about the company’s ability to continue as a going concern and notes reliance on external financing. The company also faces refinancing and litigation risk around its debt transactions, which could worsen liquidity if delayed or not completed. Operationally, cannabis businesses are exposed to regulatory change at the local, state, and federal levels, and Cannabist’s multi-jurisdiction model increases compliance complexity. More broadly, the sector is vulnerable to pricing pressure, inflation in labor and operating costs, and difficulty retaining qualified personnel in a financially stressed industry.
- Going-concern uncertaintyImpact: CriticalLikelihood: High
The company has sustained significant losses, negative operating cash flow, limited cash, and substantial debt obligations, creating doubt about its ability to continue without additional financing.
Exposure - Debt transaction delay or failureImpact: CriticalLikelihood: High
Management states the 2025 Debt Transaction may be delayed or not completed due to litigation, which could trigger significant liquidity challenges.
Exposure: Refinancing and near-term debt maturity management
- Cannabis regulatory changeImpact: HighLikelihood: Medium
Revenue and operating permissions depend on state and federal cannabis laws, which can change and affect store openings, product sales, and compliance costs.
Exposure - Personnel retention and hiringImpact: MediumLikelihood: High
The company says it may have difficulty retaining or hiring qualified personnel due to challenging financial conditions.
Exposure - Inflation and cost pressureImpact: Medium
Rising inflation can increase labor, energy, and supply costs, while the company may not be able to pass those increases through to customers.
Exposure: Store-level and cultivation margins
Accounting
Judgemental itemsManagement discloses substantial doubt about continuing as a going concern, which is a critical signal for liquidity, valuation, and balance-sheet analysis.
Impact: May affect asset recoverability, liability classification, and investor confidence
The company records derivative liabilities at fair value through profit and loss, so changes in assumptions can create non-operating gains or losses.
Impact: Can materially affect quarterly earnings volatility
The business has significant debt obligations and has incurred creditor and legal fees related to financing transactions.
Impact: Affects interest expense, amortization, and liquidity analysis
Dispensaries and cultivation/manufacturing sites create meaningful lease obligations and right-of-use assets.
Impact: Affects leverage, fixed-charge burden, and operating cash flow interpretation
Similar listed companies
Publicly listed companies with a comparable business focus.
Planet 13 Holdings Inc.
PLNH · Agricultural Production-Crops
Cannaisseur Group Inc.
TCRG · Medicinal Chemicals & Botanical Products
Charlie's Holdings, Inc.
CHUC · Medicinal Chemicals & Botanical Products
Trulieve Cannabis Corp.
TRLV · Medicinal Chemicals & Botanical Products
Target Group Inc.
CBDY · Medicinal Chemicals & Botanical Products
Cannapharmarx, Inc.
CPMD · Pharmaceutical Preparations
Last updated: 24/09/2026